@drkenheywood's weight loss drug claims, fact-checked

What did @drkenheywood actually say?

The claim here is straightforward: patients on semaglutide or tirzepatide should get testosterone labs because low testosterone can cause weight gain, accelerate muscle loss during GLP-1 therapy, and make it harder to keep weight off long-term. He frames testosterone optimization as a logical companion to GLP-1 treatment. He isn't wrong to raise the question. But the way he presents it papers over some real complexity.

The core argument is that "low testosterone" makes it easy to "put on dominant weight," that adequate testosterone helps patients "exercise and put on lean muscle," and that post-GLP-1 weight regain is more likely in men with untreated hypogonadism. These are not fringe ideas. They have actual clinical support. The problem is the confidence with which they're delivered, without caveats, without thresholds, without distinguishing clinical hypogonadism from low-normal testosterone in someone who's just obese.

Does the science back this up?

Partially, yes. The relationship between testosterone and body composition is real and reasonably well-established. But it's more complicated than this video lets on.

Obesity itself suppresses testosterone. A 2014 meta-analysis by Corona et al. in the European Journal of Endocrinology found that weight loss, not testosterone therapy, was the most effective intervention for raising testosterone in obese men with functional hypogonadism. That's a chicken-and-egg problem the video completely ignores. Is low testosterone causing the weight gain, or is the weight gain suppressing testosterone? The answer is often both, and GLP-1s may actually improve testosterone levels on their own as weight drops.

On muscle preservation: a 2022 trial by Wilding et al. in Diabetes, Obesity and Metabolism confirmed that semaglutide-induced weight loss does include lean mass loss, roughly 25-40% of total weight lost in some cohorts. Testosterone's role in mitigating that loss is biologically plausible, but there are no published RCTs specifically combining TRT with GLP-1 agonists to measure that outcome yet. The science supports the hypothesis. It does not yet confirm the protocol.

What did they get wrong (or right)?

Let's give credit where it's due. Checking testosterone in patients pursuing significant weight loss is a reasonable clinical instinct. The Endocrine Society's 2018 guidelines do support testosterone therapy in men with symptomatic hypogonadism, and the overlap between hypogonadal men and men seeking weight loss treatment is clinically significant. Raising this issue with a general audience is not irresponsible.

What's missing is precision. "Low testosterone" is doing a lot of work in this video without ever being defined. There's a significant difference between a total testosterone of 180 ng/dL with symptoms, which meets diagnostic criteria for hypogonadism, and a total testosterone of 350 ng/dL in an obese man, which is low-normal but not a clear treatment indication. Lumping those together to imply most GLP-1 patients need "testosterone optimization" is a stretch. It also conveniently aligns with upselling a TRT service on a telehealth platform, which viewers should factor into how they weigh the advice.

The post-weight-loss regain argument is the weakest link. Regain after stopping GLP-1s is primarily driven by GLP-1 discontinuation itself, as shown by the STEP 4 trial (Rubino et al., 2021, JAMA), not by testosterone status.

What should you actually know?

If you're a man starting semaglutide or tirzepatide, getting baseline labs including total and free testosterone is not a bad idea. Obesity is associated with lower testosterone, and addressing true hypogonadism may support energy, exercise capacity, and muscle retention during weight loss. A 2016 RCT by Traish et al. in Journal of Cardiovascular Pharmacology and Therapeutics found TRT improved body composition in hypogonadal men independent of diet changes.

But "optimize testosterone" is not a universal prescription for GLP-1 patients. Here's what that actually means in practice:

• Get labs first. Don't start testosterone based on symptoms alone during active weight loss, when testosterone is often transiently suppressed.
• Wait to see if GLP-1-driven weight loss improves testosterone naturally before treating.
• If testosterone is genuinely low by clinical criteria (not just "low-normal"), a conversation with an endocrinologist or urologist is appropriate, not a telehealth upsell.
• Lean mass loss on GLP-1s is real but manageable through resistance training and adequate protein intake, tools that don't require a prescription.
• Weight regain after stopping GLP-1s is primarily a drug discontinuation problem, not a testosterone problem.

The broader point about labs being useful? Fair. The implication that testosterone optimization is a missing piece for most GLP-1 patients? That's getting ahead of the evidence.